Clinical significance of ≥ 50% PD‐L1 expression with the SP263 monoclonal antibody in non‐small cell lung cancer patients

BACKGROUND: PD‐L1 expression in tumor cells has been associated with the efficacy of immune checkpoint inhibitors in non‐small cell lung cancer (NSCLC). The aim of this study was to explore correlations between smoking, genetic profiles, patient outcomes, and PD‐L1 expression in NSCLC. METHODS: PD‐L...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wenbin, Song, Peng, Guo, Lei, Liu, Xiuyun, Guo, Changyuan, Ying, Jianming, Gao, Shugeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360219/
https://www.ncbi.nlm.nih.gov/pubmed/30536734
http://dx.doi.org/10.1111/1759-7714.12929

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360219/
https://www.ncbi.nlm.nih.gov/pubmed/30536734
http://dx.doi.org/10.1111/1759-7714.12929

Ejemplares similares